Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION vs PROMETH VC PLAIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fexofenadine is a selective peripheral H1-receptor antagonist that inhibits histamine release from mast cells. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. It also has weak beta-adrenergic activity.
Promethazine is a phenothiazine derivative that acts as a potent histamine H1 receptor antagonist, blocking allergic reactions; it also has anticholinergic, antiemetic, sedative, and local anesthetic effects.
Relief of symptoms of seasonal allergic rhinitis (sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes),Relief of nasal congestion associated with seasonal allergic rhinitis,Relief of symptoms of perennial allergic rhinitis,Relief of nasal congestion associated with perennial allergic rhinitis
FDA: Allergic conditions (rhinitis, urticaria, pruritus), motion sickness, nausea/vomiting, preoperative sedation, postoperative pain control (adjunct),Off-label: Nausea in pregnancy (morning sickness), vertigo, sedation in pediatric procedures
1 tablet (fexofenadine 180 mg / pseudoephedrine 240 mg) orally every 24 hours.
Adults: 1-2 tablets (each containing Promethazine 6.25 mg and Phenylephrine 5 mg) orally every 4-6 hours; maximum 12 tablets per day.
Fexofenadine: terminal half-life 14.4 hours (range 11-17 h, ~4-fold longer than IV due to enterohepatic recirculation); pseudoephedrine: terminal half-life 4.3-8 hours (alkaline urine prolongs to 16 h).
Promethazine: terminal half-life 9-16 hours (mean 12 hours) in adults; longer in elderly (13.5-18 hours) and in hepatic impairment. Phenylephrine: half-life 2-3 hours.
Fexofenadine is minimally metabolized (≤5% of dose) by the liver, primarily via CYP3A4; other minor pathways involve CYP2D6 and CYP2C9. Pseudoephedrine is partially metabolized in the liver by N-demethylation (CYP2D6) and oxidative deamination.
Primarily hepatic metabolism via CYP2D6 and other pathways; metabolites include promethazine sulfoxide and N-demethylated derivatives.
Fexofenadine: ~95% excreted unchanged in feces (80%) and urine (11-12%); pseudoephedrine: ~70-90% excreted unchanged in urine (major route).
Primarily renal; promethazine is excreted in urine as unchanged drug (approximately 6%) and as metabolites (promethazine sulfoxide and N-demethylpromethazine); less than 1% excreted in feces. Phenylephrine is primarily metabolized by MAO and COMT; renal excretion of metabolites and unchanged drug (about 16%).
Fexofenadine: 60-70% primarily to albumin and α1-acid glycoprotein; pseudoephedrine: negligible protein binding (<20%, mainly to albumin).
Promethazine: approximately 93% bound to plasma proteins (mainly albumin). Phenylephrine: approximately 95% bound to plasma proteins (mainly albumin).
Fexofenadine: 5.4-5.8 L/kg (extensive tissue distribution, ~30-40 times plasma volume); pseudoephedrine: 2.6-3.5 L/kg (distributes into body water, crosses blood-brain barrier).
Promethazine: Vd 5-17 L/kg (mean ~12 L/kg), indicating extensive tissue distribution. Phenylephrine: Vd 4-5 L/kg, also widely distributed.
Fexofenadine: ~33-40% (oral, decreased by fruit juices); pseudoephedrine: ~85-100% (oral, minimally affected by food).
Oral promethazine: approximately 25% due to extensive first-pass metabolism. Intramuscular: nearly 100%. Rectal: approximately 70% of oral. Phenylephrine: oral bioavailability is low (about 38%) due to first-pass metabolism by MAO in gut and liver.
GFR 30-49 m L/min: 1 tablet every 24 hours; GFR 15-29 m L/min: 1 tablet every 48 hours; GFR <15 m L/min: contraindicated or not recommended.
No specific guidelines; use with caution in renal impairment (Cr Cl <30 m L/min) due to potential accumulation of promethazine; consider dose reduction or extended intervals.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C); use with caution.
Child-Pugh Class A-C: Use with caution; reduce dose or avoid in severe hepatic impairment (Child-Pugh Class C) due to decreased metabolism of promethazine.
Not recommended for children under 12 years. For age >=12 years: same as adult dosing (1 tablet every 24 hours).
Children aged 6-12 years: 1 tablet orally every 4-6 hours; maximum 6 tablets per day. Not recommended for children under 6 years due to risk of respiratory depression.
Elderly patients may have reduced renal function; assess renal function prior to use. Initial dose may be adjusted based on renal function. Avoid use in patients with hypertension or cardiovascular disease due to pseudoephedrine.
Elderly patients: Initiate at lower doses (e.g., 1 tablet orally every 6-8 hours) and titrate carefully; monitor for anticholinergic effects, sedation, and orthostatic hypotension.
None
Promethazine should not be used in children younger than 2 years due to risk of respiratory depression, including fatalities. Use in children aged 2+ with caution. Not for intra-arterial or subcutaneous injection (risk of severe tissue injury).
Cardiovascular effects (hypertension, palpitations, tachycardia, arrhythmias) especially in patients with pre-existing cardiovascular disease; CNS stimulation (insomnia, nervousness, dizziness, anxiety); risk of ischemic colitis; urinary retention (especially in patients with prostatic hypertrophy); increased intraocular pressure in patients with narrow-angle glaucoma; severe hypertension or coronary artery disease; MAOI use or within 14 days of discontinuation; use in renal impairment requires caution; avoid use with alcohol or other CNS depressants; caution in patients with hyperthyroidism, diabetes mellitus, or angle-closure glaucoma; elderly patients may be more sensitive to side effects.
Risk of respiratory depression (especially in children, elderly, or with CNS depressants); use caution in asthma, sleep apnea, respiratory insufficiency. May impair cognitive/motor function; avoid alcohol. Extrapyramidal symptoms (rare). Caution in glaucoma, prostatic hyperplasia, urinary retention. Use in pregnancy (only if clearly needed).
Concurrent use of or within 14 days after discontinuation of monoamine oxidase inhibitors (MAOIs); severe hypertension; severe coronary artery disease; narrow-angle glaucoma; urinary retention; hypersensitivity to any component
Hypersensitivity to promethazine or phenothiazines; children <2 years; comatose patients; CNS depression (e.g., alcohol, barbiturates); Reye's syndrome (avoid in children with viral illness due to risk of Reye's? – actually contraindicated in patients with suspected Reye's). Also contraindicated for intra-arterial or subcutaneous injection.
Fruit juices (apple, orange, grapefruit) significantly reduce fexofenadine absorption; take with water only. Avoid high-fat meals as they may affect pseudoephedrine absorption. No specific restrictions for pseudoephedrine, but avoid excessive caffeine (coffee, tea, cola) to reduce additive stimulant effects.
No clinically significant food interactions. However, taking with food may reduce gastrointestinal upset. Avoid grapefruit juice as it may theoretically increase sedation.
FDA Pregnancy Category C. First trimester: No adequate studies, animal studies show potential risk. Second and third trimesters: Risk unknown; associated with increased risk of gastrointestinal atresia and gastroschisis with first trimester pseudoephedrine use. Avoid in preeclampsia due to vasoconstriction.
First trimester: Avoid. Inadequate studies; animal studies not sufficient. Second/third trimester: Use only if clearly needed; may cause neonatal respiratory depression, irritability, and tremors if used near term.
Lactation Risk Category L3 (Moderately Safe). Fexofenadine excreted in breast milk in low amounts; M/P ratio not established. Pseudoephedrine excreted into breast milk with estimated relative infant dose 4.3% of maternal weight-adjusted dose. May reduce milk production and cause irritability in infants.
Promethazine is excreted into breast milk in small amounts; M/P ratio unknown. Caution suggested; avoid in infants with apnea, respiratory issues, or in mothers of preterm infants.
Pregnancy increases clearance of fexofenadine; however, no specific dose adjustment recommended. Dose of pseudoephedrine should be limited to lowest effective dose due to potential vasoconstriction. Avoid extended-release formulations in pregnancy if rapid delivery is anticipated.
No standard dose adjustment required during pregnancy. Use lowest effective dose; monitor for increased sedation and anticholinergic effects due to physiological changes.
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION contains fexofenadine 180 mg and pseudoephedrine 240 mg extended-release. Avoid in severe hypertension, coronary artery disease, narrow-angle glaucoma, urinary retention, and concurrent MAOI use or within 14 days. CNS stimulation possible; monitor for insomnia, nervousness, and dizziness. Not recommended in patients with impaired renal function (Cr Cl < 60 m L/min) due to fexofenadine accumulation. Do not crush or chew tablet.
Promethazine is a phenothiazine derivative with antihistamine, antiemetic, sedative, and anticholinergic properties. Administer deep IM if parenteral route required; avoid intra-arterial or subcutaneous injection due to risk of severe tissue damage. Monitor for extrapyramidal symptoms in children and elderly. Use with caution in patients with asthma, COPD, or sleep apnea due to respiratory depression risk. Do not use in children <2 years due to risk of fatal respiratory depression.
Take one tablet daily with water; do not crush or chew.,Avoid taking with fruit juices (e.g., apple, orange, grapefruit) as they may decrease absorption.,Do not use with other products containing pseudoephedrine or antihistamines.,Stop and consult doctor if symptoms do not improve within 7 days or are accompanied by fever.,Avoid alcohol and sedatives as they may increase dizziness.,Discontinue if signs of hypertension or tachycardia occur.,Contraindicated within 14 days of stopping MAOIs.,Pregnant or nursing women should consult a physician before use.
Do not drive or operate heavy machinery until you know how this medication affects you, as it can cause drowsiness and dizziness.,Avoid alcohol and other central nervous system depressants while taking this medication.,Take exactly as prescribed; do not exceed recommended dose or duration.,Contact your healthcare provider if you experience difficulty breathing, involuntary muscle movements, or signs of jaundice (yellowing of skin/eyes).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION vs PROMETH VC PLAIN, answered by our medical review team.
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION is a Antihistamine-Decongestant Combination that works by Fexofenadine is a selective peripheral H1-receptor antagonist that inhibits histamine release from mast cells. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. It also has weak beta-adrenergic activity.. PROMETH VC PLAIN is a Antihistamine-decongestant combination that works by Promethazine is a phenothiazine derivative that acts as a potent histamine H1 receptor antagonist, blocking allergic reactions; it also has anticholinergic, antiemetic, sedative, and local anesthetic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION and PROMETH VC PLAIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION is: 1 tablet (fexofenadine 180 mg / pseudoephedrine 240 mg) orally every 24 hours.. The standard adult dose of PROMETH VC PLAIN is: Adults: 1-2 tablets (each containing Promethazine 6.25 mg and Phenylephrine 5 mg) orally every 4-6 hours; maximum 12 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION and PROMETH VC PLAIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate studies, animal studies show potential risk. Second and third trimesters: Risk unknown; associated with increased risk of gas. PROMETH VC PLAIN is classified as Category C. First trimester: Avoid. Inadequate studies; animal studies not sufficient. Second/third trimester: Use only if clearly needed; may cause neonatal respiratory depression, irritabili. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.